EODData

FRA, 328: MEIRAGTX HLDGSDL-0000388

05 Sep 2025
LAST:

6.500

CHANGE:
 0.35
OPEN:
6.500
HIGH:
6.500
ASK:
0.000
VOLUME:
100
CHG(%):
5.69
PREV:
6.150
LOW:
6.500
BID:
0.000
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Sep 256.5006.5006.5006.500100
04 Sep 256.1506.1506.1506.150100
03 Sep 256.1506.1506.1506.150100
02 Sep 256.1006.3006.1006.300100
01 Sep 256.1006.1006.1006.100100
29 Aug 256.3006.3006.1506.150100
28 Aug 256.3006.5006.3006.500100
27 Aug 256.3506.3506.3506.350770
26 Aug 256.4006.4006.4006.400770
25 Aug 256.6006.6006.6006.600770

COMPANY PROFILE

Name:MEIRAGTX HLDGSDL-0000388
About:MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:450 East 29th Street, New York, NY, United States, 10016
Website:https://meiragtx.com
ISIN:KYG596651029
LEI:54930007YV6NYIOGFZ57

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

TECHNICAL INDICATORS

MA5:6.24
MA10:6.32
MA20:6.52
MA50:6.65
MA100:5.87
MA200:5.95
STO9:100.00
STO14:61.54
RSI14:41.30
WPR14:-38.46
MTM14:-0.25
ROC14:-0.04
ATR:0.17
Week High:6.50
Week Low:6.10
Month High:7.10
Month Low:6.10
Year High:7.54
Year Low:3.39
Volatility:25.12